The Effect of Different Macronutrients on Ileal Brake Activation

NCT ID: NCT01509469

Last Updated: 2014-01-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-03-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether ileal infusion of casein and sucrose can activate the ileal brake.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The appearance of a food matrix into the duodenum, both during a meal and during the postprandial phase results in a feed-back from different parts of the intestine to the stomach, to the small intestine and to the central nervous system. All these processes inhibit, in concert, food processing in the gastrointestinal tract, satiation and appetite sensations and, consequently, food intake. These processes are involved in the so-called intestinal brake. The location at which the feedback process is initiated determines the severity of the brake effect; the entry of nutrients into the duodenum and jejunum activates the so-called duodenal and jejunal "brakes": negative feedback mechanisms that influence the function of more proximal parts of the gastrointestinal tract. Activation of both of these feedback mechanisms results in reduction of food intake and inhibition of hunger, probably partly by inhibition of gastric emptying rate (thus contributing to enhanced and prolonged gastric distension) and small intestinal transit time. More distal in the small intestine, the ileal brake is a feedback mechanism that results in inhibition of proximal gastrointestinal motility and secretion and increase feelings of satiation and reduction of ad libitum food intake.These results all point to a potentially powerful role of the ileal brake in the regulation of digestion, with direct or indirect impact upon eating behaviour and satiation.

The current scientific data strongly suggest that activation of the ileal brake provides the most powerful feedback mechanism to gastrointestinal transit and, especially, satiety signals and food intake. Most studies have used fat as macronutrient. The effects of several amounts, types and preparations of fat on the ileal brake have previously been investigated and reported.

Until present, the effects of the other macronutrients to induce the ileal brake remain largely unknown. There is evidence that carbohydrates induce the ileal brake. Proteins may also exert effects, although data are scarce and not convincing. However, it becomes more and more accepted that proteins may induce stronger effects on satiation and food intake than fat or carbohydrates.

In this study we're going to investigate the effect of intraileal infusion of casein and sucrose on ileal brake activation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Overweight

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low dose casein

Ileal infusion of low dose casein

Group Type EXPERIMENTAL

Casein

Intervention Type DIETARY_SUPPLEMENT

Ileal infusion of low dose casein (5 gram)

High dose casein

Ileal infusion of high dose casein

Group Type EXPERIMENTAL

Casein

Intervention Type DIETARY_SUPPLEMENT

Ileal infusion of high dose casein (15 gram)

Low dose sucrose

Ileal infusion of low dose sucrose

Group Type EXPERIMENTAL

Sucrose

Intervention Type DIETARY_SUPPLEMENT

Ileal infusion of low dose sucrose (4.3 gram)

High dose sucrose

Ileal infusion of high dose sucrose

Group Type EXPERIMENTAL

Sucrose

Intervention Type DIETARY_SUPPLEMENT

Ileal infusion of high dose sucrose (12.9 gram)

Placebo

Ileal infusion saline

Group Type PLACEBO_COMPARATOR

Saline

Intervention Type OTHER

Ileal infusion with saline (180mL in total)

Safflower oil

Ileal infusion safflower oil

Group Type ACTIVE_COMPARATOR

Safflower oil

Intervention Type DIETARY_SUPPLEMENT

Ileal infusion with safflower oil (6gr safflower oil in water)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Casein

Ileal infusion of low dose casein (5 gram)

Intervention Type DIETARY_SUPPLEMENT

Casein

Ileal infusion of high dose casein (15 gram)

Intervention Type DIETARY_SUPPLEMENT

Sucrose

Ileal infusion of low dose sucrose (4.3 gram)

Intervention Type DIETARY_SUPPLEMENT

Sucrose

Ileal infusion of high dose sucrose (12.9 gram)

Intervention Type DIETARY_SUPPLEMENT

Saline

Ileal infusion with saline (180mL in total)

Intervention Type OTHER

Safflower oil

Ileal infusion with safflower oil (6gr safflower oil in water)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Based on medical history and previous examination, no gastrointestinal complaints can be defined.
* Age between 18 and 55 years. This study will include healthy adult subjects (Male and Female), Women must be taking oral contraceptives. Subjects over 55 years have an increased risk for comorbidities, therefore, subjects over 55 years will not be included.
* BMI between 18 and 29 kg/m2
* Less then 2 'yes' responses in the SCOFF questionnaire (see appendix F1)
* Weight stable over at least the last 6 months

Exclusion Criteria

* History of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol. The severity of the disease (major interference with the execution of the experiment or potential influence on the study outcomes) will be decided by the principal investigator.
* Use of medication, including vitamin supplementation, except oral contraceptives, within 14 days prior to testing
* Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study
* Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgement of the principle investigator)
* Dieting (medically prescribed, vegetarian, diabetic, macrobiological, biological dynamic)
* Pregnancy, lactation
* Excessive alcohol consumption (\>20 alcoholic consumptions per week)
* Smoking
* Blood donation within 3 months before the study period
* Self-admitted HIV-positive state
* Eating disorders detected using the 'SCOFF questionnaire' (in Dutch translation)
* Lactose or cow milk intolerance
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Top Institute Food and Nutrition

OTHER

Sponsor Role collaborator

Maastricht University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mark van Avesaat

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

A. Masclee, Prof.

Role: PRINCIPAL_INVESTIGATOR

Maastricht University Medical Centre +

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Maastricht University Medical Center

Maastricht, Limburg, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Ripken D, van Avesaat M, Troost FJ, Masclee AA, Witkamp RF, Hendriks HF. Intraileal casein infusion increases plasma concentrations of amino acids in humans: A randomized cross over trial. Clin Nutr. 2017 Feb;36(1):143-149. doi: 10.1016/j.clnu.2016.01.012. Epub 2016 Jan 29.

Reference Type DERIVED
PMID: 26872548 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL36916.068.11

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bioavailability From Chickpea Meals in Ileostomists?
NCT06921811 ENROLLING_BY_INVITATION NA
The InterSat Study
NCT04418102 COMPLETED NA
Magnesium and Vascular Stiffness
NCT02235805 COMPLETED NA